← 產業報告目錄
Intravenous Antibodies Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 121報告編號 APO-7f06a82620
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Intravenous Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Intravenous Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Intravenous Antibodies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Intravenous Antibodies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Intravenous Antibodies include Baxter, Sichuan Yuanda Shuyang, Shanghai RAAS, Octapharma, LFB Group, Kedrion, Hualan Bio, Grifols and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Intravenous Antibodies market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Intravenous Antibodies Market by Company
Baxter
Sichuan Yuanda Shuyang
Shanghai RAAS
Octapharma
LFB Group
Kedrion
Hualan Bio
Grifols
CSL
CNBG
CBPO
BPL
Biotest
Intravenous Antibodies Segment by Type
IgA
IgD
IgE
IgG
IgM
Intravenous Antibodies Segment by Application
Hospitals
Clinics
Others
Intravenous Antibodies Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Intravenous Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Intravenous Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Intravenous Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Intravenous Antibodies Market Size (2021-2032)
2.2.2 Global Intravenous Antibodies Sales (2021-2032)
2.2.3 Global Intravenous Antibodies Market Average Price (2021-2032)
2.3 Intravenous Antibodies by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 IgA
2.3.3 IgD
2.3.4 IgE
2.3.5 IgG
2.3.6 IgM
2.4 Intravenous Antibodies by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Hospitals
2.4.3 Clinics
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Intravenous Antibodies Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Intravenous Antibodies Sales (K Units) of Manufacturers (2021-2026)
3.3 Global Intravenous Antibodies Revenue of Manufacturers (2021-2026)
3.4 Global Intravenous Antibodies Average Price by Manufacturers (2021-2026)
3.5 Global Intravenous Antibodies Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Intravenous Antibodies, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Intravenous Antibodies, Product Type & Application
3.8 Global Manufacturers of Intravenous Antibodies, Established Date
3.9 Global Intravenous Antibodies Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Baxter
4.1.1 Baxter Company Information
4.1.2 Baxter Business Overview
4.1.3 Baxter Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Baxter Intravenous Antibodies Product Portfolio
4.1.5 Baxter Recent Developments
4.2 Sichuan Yuanda Shuyang
4.2.1 Sichuan Yuanda Shuyang Company Information
4.2.2 Sichuan Yuanda Shuyang Business Overview
4.2.3 Sichuan Yuanda Shuyang Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Sichuan Yuanda Shuyang Intravenous Antibodies Product Portfolio
4.2.5 Sichuan Yuanda Shuyang Recent Developments
4.3 Shanghai RAAS
4.3.1 Shanghai RAAS Company Information
4.3.2 Shanghai RAAS Business Overview
4.3.3 Shanghai RAAS Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Shanghai RAAS Intravenous Antibodies Product Portfolio
4.3.5 Shanghai RAAS Recent Developments
4.4 Octapharma
4.4.1 Octapharma Company Information
4.4.2 Octapharma Business Overview
4.4.3 Octapharma Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Octapharma Intravenous Antibodies Product Portfolio
4.4.5 Octapharma Recent Developments
4.5 LFB Group
4.5.1 LFB Group Company Information
4.5.2 LFB Group Business Overview
4.5.3 LFB Group Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.5.4 LFB Group Intravenous Antibodies Product Portfolio
4.5.5 LFB Group Recent Developments
4.6 Kedrion
4.6.1 Kedrion Company Information
4.6.2 Kedrion Business Overview
4.6.3 Kedrion Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Kedrion Intravenous Antibodies Product Portfolio
4.6.5 Kedrion Recent Developments
4.7 Hualan Bio
4.7.1 Hualan Bio Company Information
4.7.2 Hualan Bio Business Overview
4.7.3 Hualan Bio Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.7.4 Hualan Bio Intravenous Antibodies Product Portfolio
4.7.5 Hualan Bio Recent Developments
4.8 Grifols
4.8.1 Grifols Company Information
4.8.2 Grifols Business Overview
4.8.3 Grifols Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Grifols Intravenous Antibodies Product Portfolio
4.8.5 Grifols Recent Developments
4.9 CSL
4.9.1 CSL Company Information
4.9.2 CSL Business Overview
4.9.3 CSL Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.9.4 CSL Intravenous Antibodies Product Portfolio
4.9.5 CSL Recent Developments
4.10 CNBG
4.10.1 CNBG Company Information
4.10.2 CNBG Business Overview
4.10.3 CNBG Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.10.4 CNBG Intravenous Antibodies Product Portfolio
4.10.5 CNBG Recent Developments
4.11 CBPO
4.11.1 CBPO Company Information
4.11.2 CBPO Business Overview
4.11.3 CBPO Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.11.4 CBPO Intravenous Antibodies Product Portfolio
4.11.5 CBPO Recent Developments
4.12 BPL
4.12.1 BPL Company Information
4.12.2 BPL Business Overview
4.12.3 BPL Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.12.4 BPL Intravenous Antibodies Product Portfolio
4.12.5 BPL Recent Developments
4.13 Biotest
4.13.1 Biotest Company Information
4.13.2 Biotest Business Overview
4.13.3 Biotest Intravenous Antibodies Sales, Revenue and Gross Margin (2021-2026)
4.13.4 Biotest Intravenous Antibodies Product Portfolio
4.13.5 Biotest Recent Developments
5 Global Intravenous Antibodies Market Scenario by Region
5.1 Global Intravenous Antibodies Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Intravenous Antibodies Sales by Region: 2021-2032
5.2.1 Global Intravenous Antibodies Sales by Region: 2021-2026
5.2.2 Global Intravenous Antibodies Sales by Region: 2027-2032
5.3 Global Intravenous Antibodies Revenue by Region: 2021-2032
5.3.1 Global Intravenous Antibodies Revenue by Region: 2021-2026
5.3.2 Global Intravenous Antibodies Revenue by Region: 2027-2032
5.4 North America Intravenous Antibodies Market Facts & Figures by Country
5.4.1 North America Intravenous Antibodies Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Intravenous Antibodies Sales by Country (2021-2032)
5.4.3 North America Intravenous Antibodies Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Intravenous Antibodies Market Facts & Figures by Country
5.5.1 Europe Intravenous Antibodies Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Intravenous Antibodies Sales by Country (2021-2032)
5.5.3 Europe Intravenous Antibodies Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Intravenous Antibodies Market Facts & Figures by Country
5.6.1 Asia Pacific Intravenous Antibodies Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Intravenous Antibodies Sales by Country (2021-2032)
5.6.3 Asia Pacific Intravenous Antibodies Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Intravenous Antibodies Market Facts & Figures by Country
5.7.1 South America Intravenous Antibodies Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Intravenous Antibodies Sales by Country (2021-2032)
5.7.3 South America Intravenous Antibodies Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Intravenous Antibodies Market Facts & Figures by Country
5.8.1 Middle East and Africa Intravenous Antibodies Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Intravenous Antibodies Sales by Country (2021-2032)
5.8.3 Middle East and Africa Intravenous Antibodies Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Intravenous Antibodies Sales by Type (2021-2032)
6.1.1 Global Intravenous Antibodies Sales by Type (2021-2032) & (K Units)
6.1.2 Global Intravenous Antibodies Sales Market Share by Type (2021-2032)
6.2 Global Intravenous Antibodies Revenue by Type (2021-2032)
6.2.1 Global Intravenous Antibodies Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Intravenous Antibodies Revenue Market Share by Type (2021-2032)
6.3 Global Intravenous Antibodies Price by Type (2021-2032)
7 Segment by Application
7.1 Global Intravenous Antibodies Sales by Application (2021-2032)
7.1.1 Global Intravenous Antibodies Sales by Application (2021-2032) & (K Units)
7.1.2 Global Intravenous Antibodies Sales Market Share by Application (2021-2032)
7.2 Global Intravenous Antibodies Revenue by Application (2021-2032)
7.2.1 Global Intravenous Antibodies Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Intravenous Antibodies Revenue Market Share by Application (2021-2032)
7.3 Global Intravenous Antibodies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Intravenous Antibodies Value Chain Analysis
8.1.1 Intravenous Antibodies Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Intravenous Antibodies Production Mode & Process
8.2 Intravenous Antibodies Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Intravenous Antibodies Distributors
8.2.3 Intravenous Antibodies Customers
9 Global Intravenous Antibodies Analyzing Market Dynamics
9.1 Intravenous Antibodies Industry Trends
9.2 Intravenous Antibodies Industry Drivers
9.3 Intravenous Antibodies Industry Opportunities and Challenges
9.4 Intravenous Antibodies Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Intravenous Antibodies Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Intravenous Antibodies Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Intravenous Antibodies Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Intravenous Antibodies Revenue of Manufacturers (2021-2026)
Table 9. Global Intravenous Antibodies Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Intravenous Antibodies Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Intravenous Antibodies Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Intravenous Antibodies, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Intravenous Antibodies, Product Type & Application
Table 14. Global Intravenous Antibodies Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Intravenous Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Baxter Company Information
Table 19. Baxter Business Overview
Table 20. Baxter Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Baxter Intravenous Antibodies Product Portfolio
Table 22. Baxter Recent Developments
Table 23. Sichuan Yuanda Shuyang Company Information
Table 24. Sichuan Yuanda Shuyang Business Overview
Table 25. Sichuan Yuanda Shuyang Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Sichuan Yuanda Shuyang Intravenous Antibodies Product Portfolio
Table 27. Sichuan Yuanda Shuyang Recent Developments
Table 28. Shanghai RAAS Company Information
Table 29. Shanghai RAAS Business Overview
Table 30. Shanghai RAAS Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Shanghai RAAS Intravenous Antibodies Product Portfolio
Table 32. Shanghai RAAS Recent Developments
Table 33. Octapharma Company Information
Table 34. Octapharma Business Overview
Table 35. Octapharma Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Octapharma Intravenous Antibodies Product Portfolio
Table 37. Octapharma Recent Developments
Table 38. LFB Group Company Information
Table 39. LFB Group Business Overview
Table 40. LFB Group Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. LFB Group Intravenous Antibodies Product Portfolio
Table 42. LFB Group Recent Developments
Table 43. Kedrion Company Information
Table 44. Kedrion Business Overview
Table 45. Kedrion Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Kedrion Intravenous Antibodies Product Portfolio
Table 47. Kedrion Recent Developments
Table 48. Hualan Bio Company Information
Table 49. Hualan Bio Business Overview
Table 50. Hualan Bio Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Hualan Bio Intravenous Antibodies Product Portfolio
Table 52. Hualan Bio Recent Developments
Table 53. Grifols Company Information
Table 54. Grifols Business Overview
Table 55. Grifols Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Grifols Intravenous Antibodies Product Portfolio
Table 57. Grifols Recent Developments
Table 58. CSL Company Information
Table 59. CSL Business Overview
Table 60. CSL Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. CSL Intravenous Antibodies Product Portfolio
Table 62. CSL Recent Developments
Table 63. CNBG Company Information
Table 64. CNBG Business Overview
Table 65. CNBG Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. CNBG Intravenous Antibodies Product Portfolio
Table 67. CNBG Recent Developments
Table 68. CBPO Company Information
Table 69. CBPO Business Overview
Table 70. CBPO Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. CBPO Intravenous Antibodies Product Portfolio
Table 72. CBPO Recent Developments
Table 73. BPL Company Information
Table 74. BPL Business Overview
Table 75. BPL Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. BPL Intravenous Antibodies Product Portfolio
Table 77. BPL Recent Developments
Table 78. Biotest Company Information
Table 79. Biotest Business Overview
Table 80. Biotest Intravenous Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Biotest Intravenous Antibodies Product Portfolio
Table 82. Biotest Recent Developments
Table 83. Global Intravenous Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 84. Global Intravenous Antibodies Sales by Region (2021-2026) & (K Units)
Table 85. Global Intravenous Antibodies Sales Market Share by Region (2021-2026)
Table 86. Global Intravenous Antibodies Sales by Region (2027-2032) & (K Units)
Table 87. Global Intravenous Antibodies Sales Market Share by Region (2027-2032)
Table 88. Global Intravenous Antibodies Revenue by Region (2021-2026) & (US$ Million)
Table 89. Global Intravenous Antibodies Revenue Market Share by Region (2021-2026)
Table 90. Global Intravenous Antibodies Revenue by Region (2027-2032) & (US$ Million)
Table 91. Global Intravenous Antibodies Revenue Market Share by Region (2027-2032)
Table 92. North America Intravenous Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 93. North America Intravenous Antibodies Sales by Country (2021-2026) & (K Units)
Table 94. North America Intravenous Antibodies Sales by Country (2027-2032) & (K Units)
Table 95. North America Intravenous Antibodies Revenue by Country (2021-2026) & (US$ Million)
Table 96. North America Intravenous Antibodies Revenue by Country (2027-2032) & (US$ Million)
Table 97. Europe Intravenous Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 98. Europe Intravenous Antibodies Sales by Country (2021-2026) & (K Units)
Table 99. Europe Intravenous Antibodies Sales by Country (2027-2032) & (K Units)
Table 100. Europe Intravenous Antibodies Revenue by Country (2021-2026) & (US$ Million)
Table 101. Europe Intravenous Antibodies Revenue by Country (2027-2032) & (US$ Million)
Table 102. Asia Pacific Intravenous Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 103. Asia Pacific Intravenous Antibodies Sales by Country (2021-2026) & (K Units)
Table 104. Asia Pacific Intravenous Antibodies Sales by Country (2027-2032) & (K Units)
Table 105. Asia Pacific Intravenous Antibodies Revenue by Country (2021-2026) & (US$ Million)
Table 106. Asia Pacific Intravenous Antibodies Revenue by Country (2027-2032) & (US$ Million)
Table 107. South America Intravenous Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. South America Intravenous Antibodies Sales by Country (2021-2026) & (K Units)
Table 109. South America Intravenous Antibodies Sales by Country (2027-2032) & (K Units)
Table 110. South America Intravenous Antibodies Revenue by Country (2021-2026) & (US$ Million)
Table 111. South America Intravenous Antibodies Revenue by Country (2027-2032) & (US$ Million)
Table 112. Middle East and Africa Intravenous Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. Middle East and Africa Intravenous Antibodies Sales by Country (2021-2026) & (K Units)
Table 114. Middle East and Africa Intravenous Antibodies Sales by Country (2027-2032) & (K Units)
Table 115. Middle East and Africa Intravenous Antibodies Revenue by Country (2021-2026) & (US$ Million)
Table 116. Middle East and Africa Intravenous Antibodies Revenue by Country (2027-2032) & (US$ Million)
Table 117. Global Intravenous Antibodies Sales by Type (2021-2026) & (K Units)
Table 118. Global Intravenous Antibodies Sales by Type (2027-2032) & (K Units)
Table 119. Global Intravenous Antibodies Sales Market Share by Type (2021-2026)
Table 120. Global Intravenous Antibodies Sales Market Share by Type (2027-2032)
Table 121. Global Intravenous Antibodies Revenue by Type (2021-2026) & (US$ Million)
Table 122. Global Intravenous Antibodies Revenue by Type (2027-2032) & (US$ Million)
Table 123. Global Intravenous Antibodies Revenue Market Share by Type (2021-2026)
Table 124. Global Intravenous Antibodies Revenue Market Share by Type (2027-2032)
Table 125. Global Intravenous Antibodies Price by Type (2021-2026) & (US$/Unit)
Table 126. Global Intravenous Antibodies Price by Type (2027-2032) & (US$/Unit)
Table 127. Global Intravenous Antibodies Sales by Application (2021-2026) & (K Units)
Table 128. Global Intravenous Antibodies Sales by Application (2027-2032) & (K Units)
Table 129. Global Intravenous Antibodies Sales Market Share by Application (2021-2026)
Table 130. Global Intravenous Antibodies Sales Market Share by Application (2027-2032)
Table 131. Global Intravenous Antibodies Revenue by Application (2021-2026) & (US$ Million)
Table 132. Global Intravenous Antibodies Revenue by Application (2027-2032) & (US$ Million)
Table 133. Global Intravenous Antibodies Revenue Market Share by Application (2021-2026)
Table 134. Global Intravenous Antibodies Revenue Market Share by Application (2027-2032)
Table 135. Global Intravenous Antibodies Price by Application (2021-2026) & (US$/Unit)
Table 136. Global Intravenous Antibodies Price by Application (2027-2032) & (US$/Unit)
Table 137. Key Raw Materials
Table 138. Raw Materials Key Suppliers
Table 139. Intravenous Antibodies Distributors List
Table 140. Intravenous Antibodies Customers List
Table 141. Intravenous Antibodies Industry Trends
Table 142. Intravenous Antibodies Industry Drivers
Table 143. Intravenous Antibodies Industry Restraints
Table 144. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Intravenous Antibodies Product Image
Figure 5. Global Intravenous Antibodies Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Intravenous Antibodies Market Size (2021-2032) & (US$ Million)
Figure 7. Global Intravenous Antibodies Sales (2021-2032) & (K Units)
Figure 8. Global Intravenous Antibodies Average Price (US$/Unit) & (2021-2032)
Figure 9. IgA Product Image
Figure 10. IgD Product Image
Figure 11. IgE Product Image
Figure 12. IgG Product Image
Figure 13. IgM Product Image
Figure 14. Hospitals Product Image
Figure 15. Clinics Product Image
Figure 16. Others Product Image
Figure 17. Global Intravenous Antibodies Revenue Share by Manufacturers in 2025
Figure 18. Global Manufacturers of Intravenous Antibodies, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 Intravenous Antibodies Players Market Share by Revenue in 2025
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. Global Intravenous Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 22. Global Intravenous Antibodies Sales by Region in 2025
Figure 23. Global Intravenous Antibodies Revenue by Region in 2025
Figure 24. North America Intravenous Antibodies Market Size by Country in 2025
Figure 25. North America Intravenous Antibodies Sales Market Share by Country (2021-2032)
Figure 26. North America Intravenous Antibodies Revenue Market Share by Country (2021-2032)
Figure 27. United States Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Canada Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Europe Intravenous Antibodies Market Size by Country in 2025
Figure 30. Europe Intravenous Antibodies Sales Market Share by Country (2021-2032)
Figure 31. Europe Intravenous Antibodies Revenue Market Share by Country (2021-2032)
Figure 32. Germany Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. France Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. U.K. Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Italy Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Netherlands Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Asia Pacific Intravenous Antibodies Market Size by Country in 2025
Figure 38. Asia Pacific Intravenous Antibodies Sales Market Share by Country (2021-2032)
Figure 39. Asia Pacific Intravenous Antibodies Revenue Market Share by Country (2021-2032)
Figure 40. China Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Japan Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. South Korea Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. India Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Australia Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. China Taiwan Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Southeast Asia Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. Southeast Asia Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. South America Intravenous Antibodies Market Size by Country in 2025
Figure 49. South America Intravenous Antibodies Sales Market Share by Country (2021-2032)
Figure 50. South America Intravenous Antibodies Revenue Market Share by Country (2021-2032)
Figure 51. Mexico Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Brazil Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Argentina Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Colombia Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Middle East and Africa Intravenous Antibodies Market Size by Country in 2025
Figure 56. Middle East and Africa Intravenous Antibodies Sales Market Share by Country (2021-2032)
Figure 57. Middle East and Africa Intravenous Antibodies Revenue Market Share by Country (2021-2032)
Figure 58. Turkey Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Saudi Arabia Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. UAE Intravenous Antibodies Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 61. Global Intravenous Antibodies Sales Market Share by Type (2021-2032)
Figure 62. Global Intravenous Antibodies Revenue Market Share by Type (2021-2032)
Figure 63. Global Intravenous Antibodies Price (US$/Unit) by Type (2021-2032)
Figure 64. Global Intravenous Antibodies Sales Market Share by Application (2021-2032)
Figure 65. Global Intravenous Antibodies Revenue Market Share by Application (2021-2032)
Figure 66. Global Intravenous Antibodies Price (US$/Unit) by Application (2021-2032)
Figure 67. Intravenous Antibodies Value Chain
Figure 68. Intravenous Antibodies Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Intravenous Antibodies Industry Opportunities and Challenges
提及公司
BaxterSichuan Yuanda ShuyangShanghai RAASOctapharmaLFB GroupKedrionHualan BioGrifolsCSLCNBGCBPOBPLBiotest
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們